Načítá se...

Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers

In treating cancer with clinically approved chemotherapies, the high systemic toxicity and lack of selectivity for malignant cells often result in an overall poor response rate. One pharmacological approach to improve patient response is to design targeted therapies that exploit the cancer milieu by...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vielhauer, George A., Swink, Megan, Parelkar, Nikhil K., Lajiness, James P., Wolfe, Amanda L., Boger, Dale
Médium: Artigo
Jazyk:Inglês
Vydáno: Landes Bioscience 2013
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3813569/
https://ncbi.nlm.nih.gov/pubmed/23760495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24348
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!